OmniAb (OABI) Return on Capital Employed (2022 - 2026)
OmniAb's (OABI) quarterly Return on Capital Employed came in at 20.43% in Q1 2026, up 282.0% year-on-year from 5.35% in Q1 2025, and up 14.39% on a QoQ basis from 23.86% in Q4 2025.
OmniAb (OABI) Return on Capital Employed (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Return on Capital Employed data on file, last reported at 20.43% in Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 282.0% year-over-year to 20.43% in Q1 2026; TTM through Mar 2026 was 20.43%, a 282.0% increase from a year earlier, with the FY2025 full-year figure at 23.22%, down 100.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 20.43%, up from 23.86% in the prior quarter.
- Over the last five years, Return on Capital Employed for OABI reached as high as 6.8% in Q1 2023 and fell as low as 31.34% in Q3 2022.
- Historically, Return on Capital Employed has averaged 19.97% across 5 years, with a median of 23.77% in 2024.
- Across the five-year window, Return on Capital Employed surged 2085 bps in 2023 and slumped 1732 bps in 2024, its largest moves.
- Year by year, Return on Capital Employed stood at 8.78% in 2022, then tumbled by 119 bps to 19.26% in 2023, then dropped by 23 bps to 23.77% in 2024, then fell by 0 bps to 23.86% in 2025, then increased by 14 bps to 20.43% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 20.43% in Q1 2026, 23.86% in Q4 2025, and 23.87% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn | -20.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.43% |
| Dec 31, 2025 | -23.86% |
| Sep 30, 2025 | -23.87% |
| Jun 30, 2025 | -24.53% |
| Mar 31, 2025 | -23.25% |
| Dec 31, 2024 | -23.77% |
| Sep 30, 2024 | -24.95% |
| Jun 30, 2024 | -24.30% |
| Mar 31, 2024 | -24.11% |
| Dec 31, 2023 | -19.26% |
| Sep 30, 2023 | -10.49% |
| Jun 30, 2023 | -8.77% |
| Mar 31, 2023 | -6.80% |
| Dec 31, 2022 | -8.78% |
| Sep 30, 2022 | -31.34% |
| Jun 30, 2022 | -24.53% |
| Mar 31, 2022 | -16.52% |